Taurine bromamine (TauBr)--its role in immunity and new perspectives for clinical use.
This review is an attempt to summarize our knowledge about taurine bromamine (TauBr) properties, its role in innate immunity and its therapeutic potential.TauBr and taurine chloramine (TauCl) are major haloamines generated by eosinophils and neutrophils at a site of inflammation. Both haloamines share anti-inflammatory and anti-oxidant properties. TauBr, similarly to TauCl, decreases the production of proinflammatory mediators. Their anti-inflammatory and anti-oxidant activities are enhanced by their ability to induce the expression of heme oxygenase-1 (HO-1). TauCl is more stable than TauBr. On the other hand, only TauBr was found to be highly membrane-permeable showing stronger microbicidal activity than TauCl.In the light of the anti-inflammatory and antimicrobial properties of TauBr we discuss its therapeutic potential in local treatment of inflammation, especially acne vulgaris, the most common inflammatory skin disorder. TauBr, at non-cytotoxic concentrations, is able to kill Propionibacterium acnes, the skin bacteria involved in pathogenesis of acne vulgaris.As topical antibiotics used in the therapy of acne are associated with the emergence of resistant bacteria, topical TauBr seems to be a good candidate for an alternative therapy.Recently, in a double blind trial, the efficacy of TauBr was compared with the efficacy of clindamycin, one of the most common topical antibiotics used in acne therapy. Comparable reduction of acne lesions was observed in the TauBr and clindamycin groups of patients with mild and moderate inflammatory facial acne vulgaris. We conclude that this pilot study supports our concept that TauBr can be used as a topical agent in the treatment of acne vulgaris, especially in patients who have already developed antibiotic resistance. Further studies are necessary to substantiate the more extended use of TauBr as an anti-inflammatory and anti-oxidant agent in human medicine.
Marcinkiewicz
Janusz
J
Department of Immunology, Jagiellonian University Medical College, Krakow, Poland. mmmarcin@cyf-kr.edu.pl
D000152:Acne Vulgaris / Q000188:drug therapy / Q000382:microbiology; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004804:Eosinophils / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D011425:Propionibacterium acnes / Q000187:drug effects; D013654:Taurine / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D013654:Taurine; C043410:N-chlorotaurine; C052954:N-bromotaurine
Br J Dermatol. 2002 Feb;146(2):202-9
11903228
Free Radic Res. 2004 Feb;38(2):167-75
15104210
Immunol Today. 1997 Dec;18(12):577-80
9425735
Amino Acids. 2007;32(3):447-52
16868648
J Invest Dermatol. 2003 Jul;121(1):20-7
12839559
Expert Opin Pharmacother. 2007 Oct;8(15):2625-64
17931096
Immunopharmacology. 1998 Jul;40(1):27-38
9776476
Inflamm Res. 2000 Jun;49(6):280-9
10939618
Arch Immunol Ther Exp (Warsz). 2006 Jan-Feb;54(1):61-8
16642259
Antimicrob Agents Chemother. 2000 Sep;44(9):2507-13
10952603
J Leukoc Biol. 1990 Aug;48(2):174-82
2370482
Am J Trop Med Hyg. 1987 Jul;37(1):106-10
3605492
J Biol Chem. 1995 Feb 17;270(7):2906-13
7852368
J Clin Invest. 1982 Sep;70(3):598-607
6286728
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11961-6
11593004
J Leukoc Biol. 2005 May;77(5):598-625
15689384
Cutis. 2004 Jun;73(6 Suppl):6-10
15228128
J Biol Chem. 2001 Mar 16;276(11):7867-75
11096071
J Leukoc Biol. 1997 Feb;61(2):161-6
9021921
Br J Dermatol. 1989 Jul;121(1):51-7
2527056
Br J Dermatol. 2003 Sep;149(3):590-7
14510994
Amino Acids. 2004 Aug;27(1):29-35
15309569
Inflamm Res. 2005 Jan;54(1):42-9
15723204
Postgrad Med J. 1999 Jun;75(884):328-31
10435165
Eur J Dermatol. 2008 Jul-Aug;18(4):433-9
18573718
Drugs. 2004;64(21):2389-97
15481998
Inflamm Res. 2007 Nov;56(11):479-86
18224289